|1.||Szmitkowski, Maciej: 11 articles (02/2012 - 01/2007)|
|2.||Pontisso, Patrizia: 8 articles (12/2015 - 06/2005)|
|3.||Sugino, Norihiro: 8 articles (06/2010 - 02/2004)|
|4.||Nawata, Shugo: 8 articles (06/2010 - 02/2004)|
|5.||Murakami, Akihiro: 8 articles (06/2010 - 02/2004)|
|6.||Fassina, G: 6 articles (10/2015 - 02/2004)|
|7.||Pontisso, P: 6 articles (10/2015 - 02/2004)|
|8.||Sueoka, Kotaro: 6 articles (06/2010 - 02/2004)|
|9.||Takeda, Osamu: 6 articles (01/2008 - 02/2004)|
|10.||Kato, Hiroshi: 6 articles (11/2006 - 02/2004)|
09/01/2015 - "Patients with pretreatment SCC-Ag >1.86 ng/mL or posttreatment SCC-Ag >0.9 ng/mL should be considered at high risk for cancer recurrence after complete remission, and therefore, closer surveillance is needed."
02/01/2015 - "2010, the data of un-controlled cases(patients whose serum level of SCC- Ag failed to decrease to normal level or patients with incomplete tumor extinction)were eliminated, there were 1 394 cases of complete remission were analyzed, the median age was 46 years( rang, 18-72 years). "
06/01/2005 - "Multivariate Cox regression models considering tumor stage, lymph node involvement, patients' age, and SCC-Ag serum levels as covariates showed that lymph node involvement (P = 0.04 and P = 0.01) and tumor stage (P = 0.006 and P = 0.009), but not SCC-Ag serum levels (P = 0.8 and P = 0.6), and patients' age (P = 0.08 and P = 0.22) are prognostic factors for disease-free and overall survival, respectively. "
04/01/1988 - "The present study indicates that SCC antigen determination is not useful for the early diagnosis of cervical cancer, but it is a potential means for monitoring the efficacy of individual anticancer therapy of SCC of the uterine cervix and for detecting recurrent disease."
10/01/2001 - "As long as treatment possibilities for recurrent cervical cancer patients are not improved, serum SCC-ag analysis should not be carried out in routine follow-up."
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/01/2007 - "The aim of the present study was to evaluate the tissue expression of squamous cell carcinoma antigen (SCCA) in oesophageal dysplasia and squamous cell carcinoma (SCC) with reference to its clinico-pathologic and prognostic significance. "
02/01/2007 - "Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma."
10/01/2002 - "The aim of this study was to retrospectively examine whether the occurrence of squamous cell carcinoma (SCC) antigen tumour marker in the serum has prognostic significance in operable SCC of the cervix at the International Federation of Gynaecology and Obstetrics (FIGO) stages IA2-IIB. "
02/20/2001 - "[Study on change of SCC Ag, CEA and CA15-3 in rat model of lung squamous cell carcinoma]."
02/17/1996 - "The values of the squamous cell carcinoma (SCC) antigen in benign diseases were studied with the aim of determining false positive values in the study of epidermoid carcinomas. "
|3.||Vulvar Neoplasms (Vulvar Cancer)
06/21/1999 - "In summary, our data indicate that serum concentrations of SCC-Ag may be an additional independent prognostic factor of disease-free and overall survival in patients with vulvar cancer."
09/01/2002 - "In this retrospective trial, preoperative serum levels of SCC-Ag in 29 patients with invasive squamous cell vulvar cancer (pT1 + 2) were evaluated and compared with nodal status. "
06/01/2005 - "SCC-Ag serum levels cannot be used as an additional prognostic parameter in patients with surgically treated early stage vulvar cancer."
06/01/2005 - "Mean (standard deviation) SCC-Ag serum levels in patients with vulvar cancer were 1.5 (1.99) ng/mL. SCC-Ag serum levels were significantly higher in patients with pT2 vulvar cancer (2.2 [2.6] ng/mL) compared with patients with pT1 vulvar cancer (1.0 [1.2] ng/mL, P = 0.034). "
06/01/2005 - "SCC-Ag serum levels were measured preoperatively in 61 surgically staged patients with squamous cell vulvar cancer (UICC pT1 and pT2). "
12/01/2006 - "Group C patients were in complete remission after previous definitive treatment for histologically confirmed cervical carcinoma but had elevated serum squamous cell carcinoma antigen (tumour marker) levels despite negative CT-MRI. "
01/01/2009 - "This study was to investigate the significance of pretreatment serum CYFRA21-1 and squamous cell carcinoma antigen (SCCAg) in diagnosis and their correlations to the clinicopathologic features of cervical carcinoma. "
01/01/1995 - "Squamous cell carcinoma antigen (SCCA) has shown in different studies to be an effective means of monitoring the course of the disease in cervical carcinoma. "
11/01/1992 - "The results of our study indicated that the determination of SCC antigen would be clinically useful for monitoring clinical courses of patients with uroepithelial carcinomas containing SCC component and of those with pure TCC whose pretreatment level was elevated."
01/01/1992 - "The work presents the results of studies on the behaviour of SCC antigen in 52 patients aged 21-70 years, with pathologic changes involving the uterine cervix and classified to the groups of erosion, dysplasia and carcinoma in different stage of advancement. "
|5.||Neoplasm Metastasis (Metastasis)
03/01/2015 - "Primary sites in the oral cavity, in the hypopharynx, advanced T and N classification, distant metastasis, and SCC-Ag were negatively associated with survival in univariate analysis. "
02/01/2015 - "The level of SCC- Ag >5 µg/L from the patients with pelvic wall recurrence and distant metastasis were much higher than that of patients with central recurrence (P < 0.01), and the same results were shown between distant metastasis group and pelvic wall recurrent group (P < 0.01). "
01/01/2015 - "SCC-Ag level is not a good predictor for pelvic and paraaortic lymph node metastasis. "
01/01/2015 - "The areas under ROC curves between SCC-Ag level and pelvic lymph node metastasis, paraaotic lymph node metastasis, parametrial involvements were low. "
01/01/2015 - "Receiver operating characteristic (ROC) curves were used to identify the best cut-off point of SCC-Ag level to predict lymph node metastasis. "
|1.||squamous cell carcinoma-related antigen
|3.||Biological Tumor Markers (Tumor Markers)
|4.||Macrophage Colony-Stimulating Factor
|6.||urinary gonadotropin fragment
|7.||tetraiodothyroacetic acid (TA(4))
|9.||Phosphopyruvate Hydratase (Enolase)
|10.||Tissue Polypeptide Antigen
|3.||Drug Therapy (Chemotherapy)